| Dr Muhammad Rehman, MD | |
|
503 Omni Dr, Hillsborough, NJ 08844-4528 | |
| (908) 899-1549 | |
| (206) 202-3153 |
| Full Name | Dr Muhammad Rehman |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 26 Years |
| Location | 503 Omni Dr, Hillsborough, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154344786 | NPI | - | NPPES |
| 0198315 | Medicaid | NJ |
| Facility Name | Location | Facility Type |
|---|---|---|
| Robert Wood Johnson University Hospital - Somerset | Somerville, NJ | Hospital |
| Jfk Medical Center | Edison, NJ | Hospital |
| Robert Wood Johnson University Hospital At Rahway | Rahway, NJ | Hospital |
| Entity Name | Robert Wood Johnson Medical Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902848625 PECOS PAC ID: 8628065117 Enrollment ID: O20040427001205 |
News Archive
RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutics, and EyeGate Pharma, the leader in non-invasive ocular drug delivery announced today that they will collaborate on the ocular delivery of RNAi therapeutics. Each party will contribute technology, expertise, and resources to the collaboration.
FDA & USDA announced today they have approved SALMONELEX as a "GRAS" (Generally Recognized as Safe) food processing aid against Salmonella. The new product consists of natural phages against Salmonella and is produced by Micreos of The Netherlands. The company confirms that industrial scale projects with US poultry processors will start in January 2014.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its completed Phase 3 Lymphoseek studies in breast cancer and melanoma are being presented at the 32nd Congress of the European Society of Surgical Oncology (ESSO) in Valencia, Spain, from September 19-21, 2012.
Results from a five-year study of treatment-naïve patients with relapsing-remitting multiple sclerosis (RRMS) demonstrated that patients treated with COPAXONE (glatiramer acetate injection) showed significant reduced loss of brain volume compared to patients treated with other disease modifying therapies.
Every year millions of babies and toddlers receive general anesthesia for procedures ranging from hernia repair to ear surgery. Now, researchers at Mayo Clinic in Rochester have found a link among children undergoing multiple surgeries requiring general anesthesia before age 2 and learning disabilities later in childhood.
› Verified 4 days ago
| Entity Name | Nbimc Department Of Heart |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497712632 PECOS PAC ID: 9032176516 Enrollment ID: O20041216000172 |
News Archive
RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutics, and EyeGate Pharma, the leader in non-invasive ocular drug delivery announced today that they will collaborate on the ocular delivery of RNAi therapeutics. Each party will contribute technology, expertise, and resources to the collaboration.
FDA & USDA announced today they have approved SALMONELEX as a "GRAS" (Generally Recognized as Safe) food processing aid against Salmonella. The new product consists of natural phages against Salmonella and is produced by Micreos of The Netherlands. The company confirms that industrial scale projects with US poultry processors will start in January 2014.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its completed Phase 3 Lymphoseek studies in breast cancer and melanoma are being presented at the 32nd Congress of the European Society of Surgical Oncology (ESSO) in Valencia, Spain, from September 19-21, 2012.
Results from a five-year study of treatment-naïve patients with relapsing-remitting multiple sclerosis (RRMS) demonstrated that patients treated with COPAXONE (glatiramer acetate injection) showed significant reduced loss of brain volume compared to patients treated with other disease modifying therapies.
Every year millions of babies and toddlers receive general anesthesia for procedures ranging from hernia repair to ear surgery. Now, researchers at Mayo Clinic in Rochester have found a link among children undergoing multiple surgeries requiring general anesthesia before age 2 and learning disabilities later in childhood.
› Verified 4 days ago
| Entity Name | State Of New Jersey Omb Centralized Payroll |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811931504 PECOS PAC ID: 6406742592 Enrollment ID: O20050104000058 |
News Archive
RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutics, and EyeGate Pharma, the leader in non-invasive ocular drug delivery announced today that they will collaborate on the ocular delivery of RNAi therapeutics. Each party will contribute technology, expertise, and resources to the collaboration.
FDA & USDA announced today they have approved SALMONELEX as a "GRAS" (Generally Recognized as Safe) food processing aid against Salmonella. The new product consists of natural phages against Salmonella and is produced by Micreos of The Netherlands. The company confirms that industrial scale projects with US poultry processors will start in January 2014.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its completed Phase 3 Lymphoseek studies in breast cancer and melanoma are being presented at the 32nd Congress of the European Society of Surgical Oncology (ESSO) in Valencia, Spain, from September 19-21, 2012.
Results from a five-year study of treatment-naïve patients with relapsing-remitting multiple sclerosis (RRMS) demonstrated that patients treated with COPAXONE (glatiramer acetate injection) showed significant reduced loss of brain volume compared to patients treated with other disease modifying therapies.
Every year millions of babies and toddlers receive general anesthesia for procedures ranging from hernia repair to ear surgery. Now, researchers at Mayo Clinic in Rochester have found a link among children undergoing multiple surgeries requiring general anesthesia before age 2 and learning disabilities later in childhood.
› Verified 4 days ago
| Entity Name | M U Rehman Md Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477840262 PECOS PAC ID: 1850579319 Enrollment ID: O20110705000137 |
News Archive
RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutics, and EyeGate Pharma, the leader in non-invasive ocular drug delivery announced today that they will collaborate on the ocular delivery of RNAi therapeutics. Each party will contribute technology, expertise, and resources to the collaboration.
FDA & USDA announced today they have approved SALMONELEX as a "GRAS" (Generally Recognized as Safe) food processing aid against Salmonella. The new product consists of natural phages against Salmonella and is produced by Micreos of The Netherlands. The company confirms that industrial scale projects with US poultry processors will start in January 2014.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its completed Phase 3 Lymphoseek studies in breast cancer and melanoma are being presented at the 32nd Congress of the European Society of Surgical Oncology (ESSO) in Valencia, Spain, from September 19-21, 2012.
Results from a five-year study of treatment-naïve patients with relapsing-remitting multiple sclerosis (RRMS) demonstrated that patients treated with COPAXONE (glatiramer acetate injection) showed significant reduced loss of brain volume compared to patients treated with other disease modifying therapies.
Every year millions of babies and toddlers receive general anesthesia for procedures ranging from hernia repair to ear surgery. Now, researchers at Mayo Clinic in Rochester have found a link among children undergoing multiple surgeries requiring general anesthesia before age 2 and learning disabilities later in childhood.
› Verified 4 days ago
| Entity Name | Jersey Intensivist Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255776951 PECOS PAC ID: 3971746470 Enrollment ID: O20130903000343 |
News Archive
RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutics, and EyeGate Pharma, the leader in non-invasive ocular drug delivery announced today that they will collaborate on the ocular delivery of RNAi therapeutics. Each party will contribute technology, expertise, and resources to the collaboration.
FDA & USDA announced today they have approved SALMONELEX as a "GRAS" (Generally Recognized as Safe) food processing aid against Salmonella. The new product consists of natural phages against Salmonella and is produced by Micreos of The Netherlands. The company confirms that industrial scale projects with US poultry processors will start in January 2014.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its completed Phase 3 Lymphoseek studies in breast cancer and melanoma are being presented at the 32nd Congress of the European Society of Surgical Oncology (ESSO) in Valencia, Spain, from September 19-21, 2012.
Results from a five-year study of treatment-naïve patients with relapsing-remitting multiple sclerosis (RRMS) demonstrated that patients treated with COPAXONE (glatiramer acetate injection) showed significant reduced loss of brain volume compared to patients treated with other disease modifying therapies.
Every year millions of babies and toddlers receive general anesthesia for procedures ranging from hernia repair to ear surgery. Now, researchers at Mayo Clinic in Rochester have found a link among children undergoing multiple surgeries requiring general anesthesia before age 2 and learning disabilities later in childhood.
› Verified 4 days ago
| Entity Name | Icu Nj Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093123309 PECOS PAC ID: 4082836697 Enrollment ID: O20141117000283 |
News Archive
RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutics, and EyeGate Pharma, the leader in non-invasive ocular drug delivery announced today that they will collaborate on the ocular delivery of RNAi therapeutics. Each party will contribute technology, expertise, and resources to the collaboration.
FDA & USDA announced today they have approved SALMONELEX as a "GRAS" (Generally Recognized as Safe) food processing aid against Salmonella. The new product consists of natural phages against Salmonella and is produced by Micreos of The Netherlands. The company confirms that industrial scale projects with US poultry processors will start in January 2014.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its completed Phase 3 Lymphoseek studies in breast cancer and melanoma are being presented at the 32nd Congress of the European Society of Surgical Oncology (ESSO) in Valencia, Spain, from September 19-21, 2012.
Results from a five-year study of treatment-naïve patients with relapsing-remitting multiple sclerosis (RRMS) demonstrated that patients treated with COPAXONE (glatiramer acetate injection) showed significant reduced loss of brain volume compared to patients treated with other disease modifying therapies.
Every year millions of babies and toddlers receive general anesthesia for procedures ranging from hernia repair to ear surgery. Now, researchers at Mayo Clinic in Rochester have found a link among children undergoing multiple surgeries requiring general anesthesia before age 2 and learning disabilities later in childhood.
› Verified 4 days ago
| Entity Name | Rwjbh Observation Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760095806 PECOS PAC ID: 5193137503 Enrollment ID: O20201209000008 |
News Archive
RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutics, and EyeGate Pharma, the leader in non-invasive ocular drug delivery announced today that they will collaborate on the ocular delivery of RNAi therapeutics. Each party will contribute technology, expertise, and resources to the collaboration.
FDA & USDA announced today they have approved SALMONELEX as a "GRAS" (Generally Recognized as Safe) food processing aid against Salmonella. The new product consists of natural phages against Salmonella and is produced by Micreos of The Netherlands. The company confirms that industrial scale projects with US poultry processors will start in January 2014.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its completed Phase 3 Lymphoseek studies in breast cancer and melanoma are being presented at the 32nd Congress of the European Society of Surgical Oncology (ESSO) in Valencia, Spain, from September 19-21, 2012.
Results from a five-year study of treatment-naïve patients with relapsing-remitting multiple sclerosis (RRMS) demonstrated that patients treated with COPAXONE (glatiramer acetate injection) showed significant reduced loss of brain volume compared to patients treated with other disease modifying therapies.
Every year millions of babies and toddlers receive general anesthesia for procedures ranging from hernia repair to ear surgery. Now, researchers at Mayo Clinic in Rochester have found a link among children undergoing multiple surgeries requiring general anesthesia before age 2 and learning disabilities later in childhood.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Muhammad Rehman, MD Po Box 7057, Watchung, NJ 07069-0799 Ph: (908) 899-1549 | Dr Muhammad Rehman, MD 503 Omni Dr, Hillsborough, NJ 08844-4528 Ph: (908) 899-1549 |
News Archive
RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutics, and EyeGate Pharma, the leader in non-invasive ocular drug delivery announced today that they will collaborate on the ocular delivery of RNAi therapeutics. Each party will contribute technology, expertise, and resources to the collaboration.
FDA & USDA announced today they have approved SALMONELEX as a "GRAS" (Generally Recognized as Safe) food processing aid against Salmonella. The new product consists of natural phages against Salmonella and is produced by Micreos of The Netherlands. The company confirms that industrial scale projects with US poultry processors will start in January 2014.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its completed Phase 3 Lymphoseek studies in breast cancer and melanoma are being presented at the 32nd Congress of the European Society of Surgical Oncology (ESSO) in Valencia, Spain, from September 19-21, 2012.
Results from a five-year study of treatment-naïve patients with relapsing-remitting multiple sclerosis (RRMS) demonstrated that patients treated with COPAXONE (glatiramer acetate injection) showed significant reduced loss of brain volume compared to patients treated with other disease modifying therapies.
Every year millions of babies and toddlers receive general anesthesia for procedures ranging from hernia repair to ear surgery. Now, researchers at Mayo Clinic in Rochester have found a link among children undergoing multiple surgeries requiring general anesthesia before age 2 and learning disabilities later in childhood.
› Verified 4 days ago
Dr. Ronald G Nahass, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 105 Raider Blvd, Suite 101, Hillsborough, NJ 08844 Phone: 908-281-0221 Fax: 908-281-0890 | |
Dr. Yusri Ali Elsayed, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 7 Wilson Cv, Hillsborough, NJ 08844 Phone: 908-874-3982 Fax: 732-909-2046 | |
Dr. Navtika R Desai, DO Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 105 Raider Blvd, Suite 200, Hillsborough, NJ 08844 Phone: 908-829-4244 Fax: 908-382-3280 | |
Dr. Eric C. Manning, M.D., PHD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 719 Us Highway 206, Suite 100, Hillsborough, NJ 08844 Phone: 908-904-9055 Fax: 908-904-9069 | |
Dr. Jebamoni Ambrose, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 245 Us Highway 206, Hillsborough, NJ 08844 Phone: 908-874-4422 Fax: 908-874-8077 | |
Dr. Lin Wu Chou, M.D. Pulmonary Disease Medicare: May Accept Medicare Assignments Practice Location: 311 Omni Dr, Hillsborough, NJ 08844 Phone: 908-281-0632 Fax: 908-281-9848 | |
Roger Haas, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 331 Route 206 Ste 2b, Hillsborough, NJ 08844 Phone: 908-308-8016 Fax: 732-463-6065 |